Javascript must be enabled to continue!
Journal of Bone and Mineral Research
View through CrossRef
Abstract
Spontaneous fractures were reported to be rare (<1%) in 1664 hospital admissions for hip fracture in the 1950s in Sweden. We report 11 fluoride-treated postmenopausal patients who developed spontaneous fractures of the femoral necks, all subcapital initially. In 7 patients who continued treatment there were later femoral neck or shaft fractures; in 6, these were bilateral (one followed a fall). In all there were 19 spontaneous fractures: 5 were asymptomatic, including 2 with deformity; 12 fractures required surgery. Five were incomplete (stress) fractures. All were treated with supplementary calcium 1 g daily; 10 had vitamin D supplementation. In all patients where the timing was known, the initial and subsequent fractures were preceded by, or associated with increased bone turnover as measured by plasma alkaline phosphatase (pAIP) (i.e., they were all “good responders”). Two had pretreatment hip fractures following falls. We compared these 11 (Group 1) and another identically treated group of 14 patients (Group 2), without spontaneous femoral fractures and not different in mean age, pretreatment vertebral fractures, years since menopause, fluoride dosage, and plasma creatinine. Group 1 had a lower (p < 0.05) index of cortical bone in the femoral neck, as assessed by the ratio “calcar width/femoral neck minimum width.” The 6 biopsied fluorotic patients from Group 1 had a higher (p < 0.05) bone fluoride content than the 4 biopsied fluorotic patients from Group 2. Furthermore, histological cortical features of thinning, increased porosity, and advanced tunneling resorption characterized Group 1 posttreatment biopsies. There were no significant differences in peak pAIP responses in the two groups. Mild asymptomatic vitamin D excess may have been a contributing factor in three Group 1 patients.
Two further treatment groups have been studied more recently by forearm single-photon absorptiometry (SPA) at two sites; a cyclic NaF group (Group 3) and a calcium ± vitamin D group (Group 4). Neither showed significant changes in forearm cortical bone density on treatment for 2 and 1.5 years, respectively, but Group 3 showed a significant increase in density at an ultradistal (60% trabecular) site. The pAIP response in Group 3 was significantly less than in Group 1. Spontaneous femoral neck or shaft fractures did not occur in either Groups 3 or 4. Therefore, we recommend: (1) Avoidance of sodium fluoride (NaF) treatment if pretreatment femoral fracture or thin femoral neck cortices exist. (2) Reduction in NaF dosage if pAIP or osteocalcin increases by over 50% of pretreatment values. (3) Cessation of NaF if femoral neck or shaft fracture occurs during treatment, and also on the attainment of early to moderate spinal fluorosis. (4) Consideration of cyclic NaF treatment, to limit overstimulation of bone turnover and to enhance mineralization.
Oxford University Press (OUP)
Title: Journal of Bone and Mineral Research
Description:
Abstract
Spontaneous fractures were reported to be rare (<1%) in 1664 hospital admissions for hip fracture in the 1950s in Sweden.
We report 11 fluoride-treated postmenopausal patients who developed spontaneous fractures of the femoral necks, all subcapital initially.
In 7 patients who continued treatment there were later femoral neck or shaft fractures; in 6, these were bilateral (one followed a fall).
In all there were 19 spontaneous fractures: 5 were asymptomatic, including 2 with deformity; 12 fractures required surgery.
Five were incomplete (stress) fractures.
All were treated with supplementary calcium 1 g daily; 10 had vitamin D supplementation.
In all patients where the timing was known, the initial and subsequent fractures were preceded by, or associated with increased bone turnover as measured by plasma alkaline phosphatase (pAIP) (i.
e.
, they were all “good responders”).
Two had pretreatment hip fractures following falls.
We compared these 11 (Group 1) and another identically treated group of 14 patients (Group 2), without spontaneous femoral fractures and not different in mean age, pretreatment vertebral fractures, years since menopause, fluoride dosage, and plasma creatinine.
Group 1 had a lower (p < 0.
05) index of cortical bone in the femoral neck, as assessed by the ratio “calcar width/femoral neck minimum width.
” The 6 biopsied fluorotic patients from Group 1 had a higher (p < 0.
05) bone fluoride content than the 4 biopsied fluorotic patients from Group 2.
Furthermore, histological cortical features of thinning, increased porosity, and advanced tunneling resorption characterized Group 1 posttreatment biopsies.
There were no significant differences in peak pAIP responses in the two groups.
Mild asymptomatic vitamin D excess may have been a contributing factor in three Group 1 patients.
Two further treatment groups have been studied more recently by forearm single-photon absorptiometry (SPA) at two sites; a cyclic NaF group (Group 3) and a calcium ± vitamin D group (Group 4).
Neither showed significant changes in forearm cortical bone density on treatment for 2 and 1.
5 years, respectively, but Group 3 showed a significant increase in density at an ultradistal (60% trabecular) site.
The pAIP response in Group 3 was significantly less than in Group 1.
Spontaneous femoral neck or shaft fractures did not occur in either Groups 3 or 4.
Therefore, we recommend: (1) Avoidance of sodium fluoride (NaF) treatment if pretreatment femoral fracture or thin femoral neck cortices exist.
(2) Reduction in NaF dosage if pAIP or osteocalcin increases by over 50% of pretreatment values.
(3) Cessation of NaF if femoral neck or shaft fracture occurs during treatment, and also on the attainment of early to moderate spinal fluorosis.
(4) Consideration of cyclic NaF treatment, to limit overstimulation of bone turnover and to enhance mineralization.
Related Results
Frequency of Common Chromosomal Abnormalities in Patients with Idiopathic Acquired Aplastic Anemia
Frequency of Common Chromosomal Abnormalities in Patients with Idiopathic Acquired Aplastic Anemia
Objective: To determine the frequency of common chromosomal aberrations in local population idiopathic determine the frequency of common chromosomal aberrations in local population...
Poster 107: The Use of Coacervate Sustained Release System to Identify the Most Potent BMP for Bone Regeneration
Poster 107: The Use of Coacervate Sustained Release System to Identify the Most Potent BMP for Bone Regeneration
Objectives:
Bone morphogenetic proteins (BMPs) belong to the transforming growth factor superfamily that were first discovered by Marshall Urist. There are 14 B...
619. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Epetraborole Dose Selection for the Treatment of Patients with Mycobacterium avium Complex (MAC) Lung Disease
619. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Epetraborole Dose Selection for the Treatment of Patients with Mycobacterium avium Complex (MAC) Lung Disease
Abstract
Background
Epetraborole (EBO) is an orally available, bacterial leucyl transfer RNA synthetase inhibitor that concentra...
LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baum
LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baum
Abstract
Background
SUL-DUR is a β-lactam/β-lactamase inhibitor combination in development for the treatment of ABC infections, ...
Abnormalities in Bone Mineral Density and Bone Histology in Thalassemia
Abnormalities in Bone Mineral Density and Bone Histology in Thalassemia
Abstract
This study demonstrated that there was extensive iron staining on trabecular surface and marked reduction in trabecular bone volume without significant alte...
593. Population Pharmacokinetic Model Development for Epetraborole and Mycobacterium avium Complex (MAC) Lung Disease Patients Using Data from Phase 1 and 2 Studies
593. Population Pharmacokinetic Model Development for Epetraborole and Mycobacterium avium Complex (MAC) Lung Disease Patients Using Data from Phase 1 and 2 Studies
Abstract
Background
Epetraborole (EBO), an orally available bacterial leucyl transfer RNA synthetase inhibitor with potent activ...
Prediction Models for Evaluation of Total-Body Bone Mass With Dual-Energy X-Ray Absorptiometry Among Children and Adolescents
Prediction Models for Evaluation of Total-Body Bone Mass With Dual-Energy X-Ray Absorptiometry Among Children and Adolescents
Objective. The performance of dual-energy x-ray absorptiometry (DXA) in identifying children with decreased bone mass is increasing, but there is no consensus regarding how to inte...
Development of porous swelling copolymeric bone anchor for orthopedic applications
Development of porous swelling copolymeric bone anchor for orthopedic applications
Bone anchors are crucial in orthopedic surgeries, aiding in fracture fixation, soft tissue reattachment, deformity correction, osteochondral defect repair, and fusion. Existing bon...

